Abstract 3209: Enzymatic enrichment of unmethylated cell-free DNA improves the sensitivity of fragmentomic analysis for the diagnosis of patients with lung cancer

Abstract Global loss of genomic DNA methylation is associated with the progression of cancer. This genome-wide hypomethylation is thought to result from increased rates of genome replication in rapidly dividing cancer cells. We leveraged this aspect of cancer biology to address the challenge of early disease detection in cell-free DNA from a cohort of lung cancer patients. We combined Tagomics’ Activace platform, which enriches unmethylated CpG sites of the genome for sequencing, with genome-wide, fragmentomic analysis on this hypomethylated DNA fraction. Using a single sample input (>5 ng of cell free DNA) Activace enables a multiomic (epigenomic and fragmentomic) read-out with only 70 M sequencing reads. We tested the utility of this approach on a small cohort of 36 patients, who presented at the clinic with symptoms of lung cancer, had a blood sample taken and went on to receive a diagnosis using gold-standard testing (imaging, pathology). The cohort contained 14 cancer-free patients, 12 patients with an early-stage (Stage I & II) diagnosis of non-small cell lung cancer and 10 patients with a late-stage (Stage III & IV) diagnosis of non-small cell lung cancer. We sequenced the cfDNA obtained from the plasma of these patients; and enriched and sequenced the unmethylated DNA fraction from the same patients, using Tagomics’ Activace platform. We compared the fragmentomics profiles of both the enriched, unmethylated DNA and the whole cfDNA and evaluated the impact of the enrichment on our ability to classify the cohort. Using a leave-one-out approach, a logistic regression classifier, trained on the end motif profiles of the Activace dataset (enriched for unmethylated CpG sites), we correctly classified all but two of the early-stage lung cancer cases (91% sensitivity, 100% specificity). By contrast, using an analogous approach in the WGS dataset (whole cfDNA) eight lung cancer cases (seven early-stage and one late-stage) were misclassified (64% sensitivity, 100% specificity). Multiomics tools, such as the Tagomics’ Activace platform enable information-rich insight into disease biology and will likely outperform single analyte-based tests, in the future. The enrichment of DNA containing unmethylated CpG sites improves sensitivity of fragmentomic analysis, relative to analogous analysis of the whole genome, likely due to the enrichment of tumour-derived, hypomethylated DNA fragments in patients with cancer. Citation Format: Valentina Miano, Paulina Siejka-Zielińska, Calum Mould, Sean Knight, Seamus Grundy, Robert K. Neely. Enzymatic enrichment of unmethylated cell-free DNA improves the sensitivity of fragmentomic analysis for the diagnosis of patients with lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 3209.

Authors

Institutions

Publication Details

Journal
Cancer Research
Published
2026-04-03
DOI
https://doi.org/10.1158/1538-7445.am2026-3209
Primary Topic
Epigenetics and DNA Methylation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract 3209: Enzymatic enrichment of unmethylated cell-free DNA improves the sensitivity of fragmentomic analysis for the diagnosis of patients with lung cancer

Robert K. Neely, Valentina Miano, Paulina Siejka-Zielińska, Seamus Grundy et al.
Cancer Research
Epigenetics and DNA Methylation
article

Abstract 3209: Enzymatic enrichment of unmethylated cell-free DNA improves the sensitivity of fragmentomic analysis for the diagnosis of patients with lung cancer

Robert K. Neely, Valentina Miano, Paulina Siejka-Zielińska, Seamus Grundy, Calum Mould, Sean Knight
article en

Abstract

Abstract Global loss of genomic DNA methylation is associated with the progression of cancer. This genome-wide hypomethylation is thought to result from increased rates of genome replication in rapidly dividing cancer cells. We leveraged this aspect of cancer biology to address the challenge of early disease detection in cell-free DNA from a cohort of lung cancer patients. We combined Tagomics’ Activace platform, which enriches unmethylated CpG sites of the genome for sequencing, with genome-wide, fragmentomic analysis on this hypomethylated DNA fraction. Using a single sample input (>5 ng of cell free DNA) Activace enables a multiomic (epigenomic and fragmentomic) read-out with only 70 M sequencing reads. We tested the utility of this approach on a small cohort of 36 patients, who presented at the clinic with symptoms of lung cancer, had a blood sample taken and went on to receive a diagnosis using gold-standard testing (imaging, pathology). The cohort contained 14 cancer-free patients, 12 patients with an early-stage (Stage I & II) diagnosis of non-small cell lung cancer and 10 patients with a late-stage (Stage III & IV) diagnosis of non-small cell lung cancer. We sequenced the cfDNA obtained from the plasma of these patients; and enriched and sequenced the unmethylated DNA fraction from the same patients, using Tagomics’ Activace platform. We compared the fragmentomics profiles of both the enriched, unmethylated DNA and the whole cfDNA and evaluated the impact of the enrichment on our ability to classify the cohort. Using a leave-one-out approach, a logistic regression classifier, trained on the end motif profiles of the Activace dataset (enriched for unmethylated CpG sites), we correctly classified all but two of the early-stage lung cancer cases (91% sensitivity, 100% specificity). By contrast, using an analogous approach in the WGS dataset (whole cfDNA) eight lung cancer cases (seven early-stage and one late-stage) were misclassified (64% sensitivity, 100% specificity). Multiomics tools, such as the Tagomics’ Activace platform enable information-rich insight into disease biology and will likely outperform single analyte-based tests, in the future. The enrichment of DNA containing unmethylated CpG sites improves sensitivity of fragmentomic analysis, relative to analogous analysis of the whole genome, likely due to the enrichment of tumour-derived, hypomethylated DNA fragments in patients with cancer. Citation Format: Valentina Miano, Paulina Siejka-Zielińska, Calum Mould, Sean Knight, Seamus Grundy, Robert K. Neely. Enzymatic enrichment of unmethylated cell-free DNA improves the sensitivity of fragmentomic analysis for the diagnosis of patients with lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 3209.

Cancer ResearchVol. 86(7_Supplement)
Salford Royal NHS Foundation Trust (GB), University of Manchester (GB), Cambridge–MIT Institute (GB)
Openalex Percentile: Top 8%
Epigenetics and DNA Methylation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.